DMPK and Degradation Metabolite Production
using Microbial Biotransformation
Hypha Discovery produces mammalian and agrochemical (microbial) metabolites for the pharmaceutical and agrochemical sectors. Through feeding parent experimental drugs or agrochemicals to fermentations of our proprietary panels of microorganisms, it is possible to mimic and scale up the metabolism that occurs in biological systems.
 |
The anticancer drug Gleevec (imatinib) forms metabolites during therapy, the N-demethyl metabolite being the most prominent. Our front-line screening panel of 12 organisms not only produces the most important metabolites, but also those that are present in lower concentration or not previously described. |
Effective production of the main Gleevec metabolites by one of the diverse panel of 12 strains. |
|
Cost-effective production of metabolites 1. Structural confirmation 2. Production of analytical standards (FDA – MIST compliance) 3. Materials for pharmacology 4. Materials for toxicology (FDA – MISTcompliance) 5. Microbial metabolites for agrochemical R&D 6. Potential to scale up to gram production |
Complementary to medicinal chemistry 1. Improve or overcome patent protection coverage 2. Access molecules not easily synthesised to broaden SAR 3. Improve solubility 4. Enzymatic addition of functional groups to expand scope for chemical lead optimisation |